Nonlinear Dynamics to Distribute GeneBio’s Phenyx Worldwide
News Jun 05, 2008
Geneva Bioinformatics (GeneBio) SA and Nonlinear Dynamics have announced a worldwide distribution agreement for GeneBio’s Phenyx and Nonlinear’s Progenesis LC-MS software, whereby Nonlinear will distribute GeneBio’s Phenyx MS identification platform.
This partnership exploits the complementary technology of Phenyx and the novel Progenesis LC-MS software for label-free quantitative analysis.
Under the terms of the agreement, Nonlinear will distribute Phenyx both as a standalone software package and alongside the Progenesis LC-MS software.
The synergy between the two products, Phenyx for MS-MS identification and Progenesis LC-MS for quantitative analysis, offers customers a comprehensive solution building on the extensive reputations of the two companies in the field of proteomics.
Developed in collaboration with the Swiss Institute of Bioinformatics (SIB), Phenyx is GeneBio’s renowned software platform for the identification and characterization of proteins and peptides from mass spectrometry data, specifically designed to meet the concurrent demands of high-throughput MS data analysis and dynamic results assessment while offering a flexible user experience and an adaptable architecture to help instil confidence in results assessment.
“This is a major step forward for Phenyx and GeneBio; we are very motivated about what this distribution deal will bring,” said Nasri Nahas, CEO of GeneBio.
“Our two companies have known and respected each other for quite some time. Nonlinear’s reputation in the bioinformatics field, their extended clientele and distribution network are all first-class; this deal allows us to bring Phenyx even closer to the MS community, especially when bundled with an innovative tool like Progenesis LC-MS. We look forward to the great upsides this new collaboration will bring to both parties and to the successful expansion of our Phenyx business,” Nahas continued.
As genome editing technologies advance toward clinical therapies, they are raising hopes of a completely new way to treat disease. However, challenges need to be addressed before potential treatments can be widely used in patients. To tackle these challenges, the National Institutes of Health has launched the Somatic Cell Genome Editing program, which has awarded multiple grants including more than $3.6 million to assess the safety of genome editing in human cells and tissues.